MMED stock forecast, quote, news & analysis
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy... Show more
Why MiniMed Group (MMED) Stock Is Down -19.7% in the Last 30 Days
Key Takeaways
- MiniMed Group (MMED) declined roughly 19.7% over the trailing 30 days, falling from $21.79 to $17.49 as investors absorbed the completion of the company's split-off from Medtronic (MDT).
- The pullback largely reversed an early-September surge that carried the stock to a 52-week high of $24.43 following strong fiscal 2027 first-quarter results.
- The sharpest selling was supply-driven: roughly 252.8 million shares were distributed through Medtronic's oversubscribed exchange offer, triggering heavy volume as former Medtronic holders repositioned.
- Over the full quarter, MMED is approximately flat to slightly higher (up about 3%), reflecting solid underlying growth offset by separation-related volatility.
- Sell-side coverage remains broadly constructive, with a consensus Buy rating and an average price target near $25, though near-term price discovery is still unfolding.
MiniMed Group (MMED) Company Overview and Market Position
MiniMed Group, Inc. is a medical technology company focused on diabetes management. It develops, manufactures, and commercializes insulin pumps, continuous glucose monitoring (CGM) systems, related consumables, smart insulin pens, and digital health solutions for people living with Type 1 and Type 2 diabetes. Its flagship product is the MiniMed 780G automated insulin delivery (AID) system, which uses the SmartGuard dosing algorithm to automatically adjust basal insulin and deliver auto-correction doses. The platform is complemented by the Simplera Sync CGM sensor and a growing pipeline that includes the MiniMed Flex pump, the MiniMed Fit patch pump, and the next-generation Vivera dosing algorithm.
Founded in 1983 and headquartered in Northridge, California, MiniMed operated as the diabetes business of Medtronic for roughly two decades before completing its initial public offering on March 6, 2026, at $20 per share. The company also maintains a CGM partnership with Abbott (ABT), positioning it as one of the few providers able to offer integrated pumps and sensors. Investors follow the stock for its recurring, consumable-driven revenue base and its opportunity to grow as an independent, more focused business.
MiniMed Group (MMED) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, MMED fell from a closing price of $21.79 to $17.49, a decline of approximately 19.7%. The move was not a straight line: the stock had already eased from its late-summer peak before accelerating lower in mid-October, when the finalization of the Medtronic separation flooded the market with newly distributed shares. The largest single-day drop occurred around October 14, when shares traded as low as $16.56 intraday before stabilizing near $18 and then settling in the upper teens.
The quarterly picture is notably different. Three months earlier, MMED closed near $16.92, meaning the stock is roughly 3% higher over that span despite the recent pullback. In short, the stock rallied strongly into early September on upbeat results and pipeline news, then gave back most of those gains as structural supply pressures and profit-taking took hold.
What Drove MMED Stock Price in the Last 30 Days
The dominant driver of the recent decline was the completion of Medtronic's separation. Medtronic launched an exchange offer allowing its shareholders to swap Medtronic stock for MiniMed shares, and the offer was oversubscribed. When the split-off closed, roughly 252.8 million MiniMed shares became freely distributable, and Medtronic ceased to hold any MiniMed equity. The resulting surge in available supply prompted selling from Medtronic investors who received shares they did not intend to keep, pressuring the stock independent of the company's operating performance.
Compounding that supply overhang was profit-taking after a sharp September rally. With the stock trading well above its IPO price, short-term holders had incentive to lock in gains once momentum faded. New analyst initiations during the period, including a Hold rating from Jefferies with a $22 price target, contributed to a more measured tone even as other firms, such as Truist, began coverage with Buy ratings. Concerns about MiniMed's ongoing net losses, cash burn, and the multi-year workload of completing its separation from Medtronic also weighed on sentiment.
What Drove MMED Stock Performance Over the Last Quarter
The quarter's broader narrative centers on MiniMed's first full results cycle as a standalone company. On September 3, MiniMed reported fiscal 2027 first-quarter revenue of $843 million, up 17% year over year, and raised its organic revenue growth guidance for the year. Management also highlighted accelerating U.S. sales, international growth, and several regulatory milestones: CE Mark approval for MiniMed Flex, an FDA submission for the MiniMed Fit patch pump, completion of enrollment in the Vivera pivotal U.S. trial, and IDE approval for a next-generation extended-wear sensor. Earlier in the quarter, MiniMed Flex gained access to Medicare and Medicare Advantage beneficiaries, expanding its reimbursable addressable market.
These developments powered the rally to the $24.43 high, and new Buy coverage from Truist with a $29 target reinforced the optimistic case. However, the same quarter also featured the structural headwind of Medtronic's roughly 90% retained stake, which created persistent uncertainty about when and how that overhang would be resolved. That uncertainty was realized in October, when the exchange offer's completion drove the give-back that now dominates the 30-day view.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are currently generating the strongest, most relevant performance. While Tickeron offers hundreds of bots trading thousands of tickers, only the top-performing and most applicable strategies appear in this featured section. The bots vary widely in strategy, trading timeframe, and performance metrics, giving traders the flexibility to identify approaches that align with their own objectives and risk tolerance. For those seeking a data-driven complement to their analysis, exploring the Trending AI Robots page can offer a practical way to see which automated strategies are resonating with current market conditions.
MMED Stock Forecast Drivers: What Investors Should Watch Next
Investors should watch MiniMed's next quarterly earnings report, expected in early November, for updated guidance on revenue growth, margins, and cash flow as the company completes its separation from Medtronic through 2027. Progress on the product pipeline will also matter: the timing of MiniMed Fit commercialization, the first data from the Vivera fully closed-loop trial, and continued adoption of the Simplera Sync CGM and the Abbott partnership are all potential catalysts. Competitive dynamics against Insulet (PODD), Tandem Diabetes Care (TNDM), and Dexcom (DXCM) remain a key variable, as do execution risks tied to manufacturing ramp-ups and margin improvement. Finally, the company's path toward sustained profitability and its liquidity position will be closely scrutinized given ongoing net losses and cash burn.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MMED's Indicator enters downward trend
The Aroon Indicator for MMED entered a downward trend on October 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 16 similar instances where the Aroon Indicator formed such a pattern. In 11 of the 16 cases the stock moved lower. This puts the odds of a downward move at 69%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MMED as a result. In 3 of 5 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MMED's RSI Oscillator exited the oversold zone, 4 of 5 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 4 of 4 cases where MMED's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +2.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where MMED advanced for three days, in 28 of 31 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
MMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.383) is normal, around the industry mean (4.952). P/E Ratio (-15.941) is within average values for comparable stocks, (36.644). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.950) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. MMED’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther